Biohaven Pharmaceutical Holding Company and Sosei Group Corporation have signed a collaboration and licensing agreement under which the former will have the exclusive global rights for developing, manufacturing and commercializing a novel, small-molecule CGRP receptor antagonist portfolio discovered by Sosei Heptares.

The portfolio has been discovered by Sosei Heptares for treating CGRP-mediated disorders. It comprises of HTL0022562, the lead candidate advanced through preclinical development where it showed promising and differentiated properties for possible investigation in human trials.

For this licensing deal, Sosei Heptares is bound to receive US$10 million in upfront payment in cash consideration and common shares of Biohaven, research funding and is further eligible to get additional milestone, regulatory and development payments of nearly US$370 million. Also, it will be eligible for receiving tiered royalties on the net sales of products developed from this partnership.

A commercial-stage biopharma company, Biohaven boasts a portfolio of novel, best-in-class therapies for enhancing the lives of patients suffering from debilitating neuropsychiatric and neurological disorders. The firm’s neuroinnovation portfolio is inclusive of NURTEC™ ODT (rimegepant), an FDA-approved treatment for migraine as well as a broad range of late-product candidates across distinct mechanistic platforms.

These platforms are glutamate modulation for obsessive-compulsive disorder, spinocerebellar ataxia and Alzheimer's disease; CGRP receptor antagonism aimed at acute and preventive treatment of migraine and myeloperoxidase (MPO) inhibition developed for amyotrophic lateral sclerosis and multiple system atrophy.

Sosei Heptares is a global biopharmaceutical  group seeking the discovery and early development of new medicines that originate from its proprietary technology GPCR-targeted StaR® and structure-based drug design platform capabilities. The company is advancing a broad portfolio of innovative medicines for several therapeutic areas, like immunology, gastroenterology, neurology and inflammatory diseases.

Source Credits: https://www.prnewswire.com/news-releases/sosei-heptares-and-biohaven-enter-global-collaboration-and-license-agreement-to-advance-novel-small-molecule-cgrp-antagonist-portfolio-301182244.html